Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis

Abstract

Cancer-associated thrombosis affects between 1 and 20% of all patients diagnosed with cancer and is associated with significant morbidity and a poorer prognosis. Risk assessment scores exist which include the measurement of biomarkers, and which aim to identify patients at a higher risk of developing thrombotic events, but these are poor predictors and rarely used in routine clinical practice.

VEGF is a potent angiogenic factor, produced by tumour cells, and released by platelets and is essential for tumour growth and progression. It also plays a role in the promotion of thrombosis through platelet activation and adhesion, and by inducing the expression of tissue factor. Therefore, the potential of VEGF to be used as a biomarker to predict cancer-associated thrombosis requires further investigation.

This study reviewed the published literature to determine whether circulating VEGF levels are associated with increased risk of venous thromboembolism in patients with cancer.

PubMed and OVID databases were systematically searched according to PRISMA guidelines for relevant papers using the keywords “cancer” AND “thrombosis” AND “VEGF” up to July 2023. Inclusion and exclusion criteria were applied.

Seven papers (1,528 participants) were identified and included in the meta-analysis, three of which (922 participants) measured VEGF before a thrombotic event, and the remaining four (606 participants) measured VEGF at the time of the thrombosis. Our results showed that although plasma and serum VEGF tended to be higher in those who subsequently developed thrombosis than those who did not (mean difference 70.2 pg/mL for serum, and 11.44 pg/mL for plasma VEGF, 95% CI −2.39–25.73, p = 0.10), this was not found to be statistically significant. However, analysis of VEGF following blood sampling at the time of thrombosis showed a stronger statistically significant association between increased VEGF levels and presence of thrombosis (mean difference 117.02 pg/mL for serum, and 116.6 pg/mL for plasma VEGF, 95% CI 55.42–190.82, p = 0.0004).

Based on current studies, whilst it is increased at the time of thrombosis, VEGF is not effective as a predictive biomarker of CAT.

Keywords

VEGF - cancer - thrombosis - biomarker

Authors' Contributions

A.M.B., K.M., and A.J.U. were responsible for the conceptualization of the study, while resources were provided by A.M.B. The original draft was prepared by A.M.B. and A.J.U., with review and editing contributions from A.M.B., S.N., K.M., and A.J.U. Visualization was carried out by A.M.B., and the project was supervised by K.M. and A.J.U. Project administration and funding acquisition were managed by A.M.B. All authors have reviewed, read, and approved the final version of the manuscript. Furthermore, none of the authors have any competing interests to declare.

Publication History

Received: 25 May 2024

Accepted: 06 January 2025

Accepted Manuscript online:
10 January 2025

Article published online:
10 February 2025

• References

• 1 Dogan M, Demirkazik A. Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. Support Cancer Ther 2005; 3 (01) 28-34
• 2 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (04) 458-464
• 3 van Es N, Di Nisio M, Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102 (09) 1494-1501
• 4 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
• 5 Watson HG, Keeling DM, Laffan M, Tait RC, Makris M. British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170 (05) 640-648
• 6 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
• 7 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
• 8 Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thromb Res 2020; 191 (Suppl. 01) S3-S11
• 9 Li X, Feng G-S, Zheng C-S, Zhuo C-K, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19) 2878-2882
• 10 Dogan M, Demirkazik A, Konuk N. et al. The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study. Int J Biol Markers 2006; 21 (04) 206-210
• 11 Posch F, Thaler J, Zlabinger GJ. et al. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: result from the Vienna cancer and thrombosis study. Clin Cancer Res 2016; 22 (01) 200-206
• 12 Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5 (03) 487-491
• 13 Wang Y, Zhang Z, Tao P, Reyila M, Qi X, Yang J. The abnormal expression of miR-205-5p, miR-195-5p, and VEGF-A in human cervical cancer is related to the treatment of venous thromboembolism. BioMed Res Int 2020; 2020: 3929435
• 14 Page MJ, McKenzie JE, Bossuyt PM. et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 2021; 134: 103-112
• 15 Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008; 99 (07) 1000-1006
• 16 Kirwan CC, Byrne GJ, Kumar S, McDowell G. Platelet release of vascular endothelial growth factor (VEGF) in patients undergoing chemotherapy for breast cancer. J Angiogenes Res 2009; 1 (01) 7
• 17 Wells GA, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021 . Assessed November 18, 2023 at: https://ohri.ca/programs/clinical_epidemiology/oxford.asp
• 18 Page MJ, Sterne JAC, Boutron I. et al. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. BMJ 2023; 383: e076754
• 19 Cacciola RR, Di Francesco E, Giustolisi R, Cacciola E. Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications. Haematologica 2002; 87 (07) 774-775
• 20 Nazari PMS, Marosi C, Moik F. et al. Low systemic levels of chemokine C–C motif ligand 2 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma. Cancers (Basel) 2019; 11 (12) 2020
• 21 Musolino C, Calabro' L, Bellomo G. et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002; 69 (03) 159-163
• 22 Kim SJ, Choi IK, Park KH. et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 2004; 34 (04) 184-190
• 23 Ramadan HK, Meghezel EM, Abdel-Malek MO. et al. Correlation between vascular endothelial growth factor and long-term occurrence of HCV-related hepatocellular carcinoma after treatment with direct-acting antivirals. Cancer Invest 2021; 39 (08) 653-660
• 24 Malaponte G, Signorelli SS, Bevelacqua V. et al. Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis. PLoS One 2015; 10 (07) e0132496
• 25 Khorana AA, Ahrendt SA, Ryan CK. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13 (10) 2870-2875
• 26 Zhang Y, Deng Y, Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94 (03) 1320-1327
• 27 Echrish H, Madden LA, Greenman J, Maraveyas A. The hemostasis apparatus in pancreatic cancer and its importance beyond thrombosis. Cancers (Basel) 2011; 3 (01) 267-284
• 28 Verheul HM, Hoekman K, Luykx-de Bakker S. et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3 (12 Pt 1): 2187-2190
• 29 D'Souza A, Hayman SR, Buadi F. et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011; 118 (17) 4663-4665
• 30 Kraft A, Weindel K, Ochs A. et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85 (01) 178-187
• 31 Cohen AT, Spiro TE, Spyropoulos AC. et al; MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014; 12 (04) 479-487
• 32 Tan X, Chen G, Liu Y. et al. Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy. Sci Rep 2017; 7 (01) 4836
• 33 Hansen E-S, Rinde FB, Edvardsen MS. et al. Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism. Thromb Res 2021; 208: 121-126
• 34 Linkins L-A, Takach Lapner S. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol 2017; 39 (Suppl. 01) 98-103
• 35 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
• 36 Swamy S, Ueland T, Hansen J-B, Snir O, Brækkan SK. Plasma levels of P-selectin and future risk of incident venous thromboembolism. J Thromb Haemost 2023; 21 (09) 2451-2460